Treace Medical Concepts, INC Form 4 insider transactions

Treace Medical Concepts' Chief Innovation Officer, Sean F. Scanlan, reported a disposition of 208 common shares for tax withholding purposes.

Scot Elder, Chief Legal & Compliance Officer of Treace Medical Concepts, Inc., reported a disposition of 984 common shares related to tax withholding.

Scot Elder, Chief Legal & Compliance Officer of Treace Medical Concepts, disposed of common stock to cover tax liabilities related to RSU vesting.

A Treace Medical Concepts officer disposed of 10,515 common shares to satisfy tax withholding obligations related to equity awards.

Treace Medical Concepts CFO Mark Hair disposed of 22,212 common shares for tax withholding purposes, retaining 518,964 shares.

Treace Medical Concepts' Chief Innovation Officer, Sean Scanlan, disposed of 9,814 common shares to cover tax obligations related to equity vesting.

Treace Medical Concepts' SVP of Sales, Aaron Berutti, filed a Form 4 indicating a future disposition of 4,907 common shares on August 9, 2025, to cover tax withholding obligations.

Treace Medical Concepts' Chief Innovation Officer, Sean F. Scanlan, exercised stock options to acquire 33,437 shares and transferred 13,897 shares due to a domestic relations order.

Director Deepti Jain reports acquisition of restricted stock units and disposal of common stock.

Director Lance A. Berry reports acquisition and disposal of Treace Medical Concepts (TMCI) stock, including restricted stock units, in a recent SEC filing.

Lawrence Hamilton, a director at Treace Medical Concepts, reported the acquisition of 23,917 shares of common stock through restricted stock units and the disposal of 44,056 shares.

Director Jane E. Kiernan reports acquisition of 23,917 shares and disposal of shares of Treace Medical Concepts, Inc. common stock on May 20, 2025.

Director Betsy Hanna reported the acquisition of 23,917 shares of Treace Medical Concepts, Inc. through restricted stock units and the disposal of the same amount.

Director Richard W. Mott reports acquisition of restricted stock units and deferred receipt of shares of Treace Medical Concepts, Inc. common stock.

Director John K. Bakewell reports acquisition and disposal of Treace Medical Concepts, Inc. stock, including restricted stock units, with deferred receipt of shares.

Scot Elder, Chief Legal & Compliance Officer and Corporate Secretary of Treace Medical Concepts, reports acquisition and disposal of company stock.

Sean F. Scanlan, Chief Innovation Officer of Treace Medical Concepts, Inc., executed stock options and sold 50,000 shares of common stock on March 17, 2025, according to a Form 4 filing with the SEC.

Aaron Berutti, SVP of Sales at Treace Medical Concepts, Inc., disposed of shares to cover tax obligations related to restricted stock units.

John T. Treace, CEO of Treace Medical Concepts, reports disposition of common stock to cover tax obligations related to restricted stock units.

Sean Scanlan, Chief Innovation Officer at Treace Medical Concepts, reports disposing of shares to cover tax obligations related to restricted stock units.

Scot Elder, Chief Legal & Compliance Officer and Corporate Secretary of Treace Medical Concepts, Inc., reported the disposal of common stock to cover tax obligations related to restricted stock units.

Mark Hair, CFO of Treace Medical Concepts, Inc., reported the disposal of common stock to cover tax obligations related to restricted stock units.

CEO John T. Treace of Treace Medical Concepts, Inc. recently purchased 60,000 shares of common stock at an average price of $8.7344 per share.

Aaron Berutti, SVP of Sales at Treace Medical Concepts, acquired 75,000 shares of common stock through restricted stock units.

Sean F. Scanlan, Chief Innovation Officer at Treace Medical Concepts, was granted 140,625 restricted stock units, vesting over four years.

Treace Medical Concepts CEO John T. Treace was granted 225,000 restricted stock units and reports beneficial ownership of over 10 million shares of common stock.

Scot Michael Elder, Chief Legal & Compliance Officer and Corporate Secretary at Treace Medical Concepts, Inc., was granted 127,500 restricted stock units on January 22, 2025.

Treace Medical Concepts' Chief Financial Officer, Mark Hair, was granted 187,500 restricted stock units (RSUs) on January 22, 2025, which vest over four years.

Mark Hair, CFO of Treace Medical Concepts, disposed of 8,594 shares of common stock to cover tax obligations related to vesting restricted stock units.

Chief Innovation Officer of Treace Medical Concepts, Sean Scanlan, reports a transfer of shares due to a domestic relations order.